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A systematic review was conducted to identify evidence-based interventions (EBIs) for increasing 
HIV medication adherence behavior or decreasing HIV viral load among persons living with HIV 
(PLWH). We conducted automated searches of electronic databases (i.e., MEDLINE, EMBASE, 
PsycINFO, CINAHL) and manual searches of journals, reference lists, and listservs. Interventions 
were eligible for the review if they were U.S.-based, published between 1996 and 2011, intended 
to improve HIV medication adherence behaviors of PLWH, evaluated the intervention using a 
comparison group, and reported outcome data on adherence behaviors or HIV viral load. Each 
intervention was evaluated on the quality of study design, implementation, analysis, and strength 
of findings. Of the 65 eligible interventions, 10 are EBIs. The remaining 55 interventions failed to 
meet the efficacy criteria primarily due to null findings, small sample sizes, or low retention rates. 
Research gaps and future directions for development of adherence EBIs are discussed.
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Introduction
Due to the availability and advancement of highly active antiretroviral therapy (HAART) as 
well as an increasing number of persons living with HIV (PLWH), there has been an 
increased focus on both health promotion and HIV prevention for PLWH [1]. The individual 
health benefits of antiretroviral treatment (ART) for PLWH are clear [2–6]; however, the 
success of ART is related to the patient’s level of medication adherence. High adherence 
rates have consistently been associated with decreased viral load, less risk of progression to 
AIDS, and a decreased risk of developing drug-resistant strains of HIV [7–10], whereas poor 
adherence is associated with treatment failure, lower CD4 cell counts, and increased 
mortality [10–19]. Recently, the HIV Prevention Trials Network 052 study comparing early 
versus delayed ART for HIV patients with CD4 cell counts between 350 and 550 cells/mm3 
found a 96 % reduction in the number of linked HIV transmissions for those with early ART 
initiation. This finding suggests that, in addition to individual health benefits, ART has 
significant prevention benefits in that successful viral suppression can lead to a reduction in 
HIV transmission risk [20].
However, the most recent surveillance data from the Centers for Disease Control and 
Prevention (CDC) showed that among 1.15 million PLWH in the United States (U.S.) in 
2009, 33 % were prescribed ART and only 25 % were estimated to have the suppressed viral 
load needed to maximally prolong health and prevent transmission [21].
Optimal adherence to ART is critical to fully achieve both the clinical and preventive 
benefits of ART. However, a recent meta-analysis suggests that adherence levels remain 
suboptimal. In 84 studies across 20 countries, an average of 62 % of participants reported 
≥90 % adherence to HAART [22]. Maintaining high levels of adherence to medications for a 
chronic condition is extremely difficult and often requires additional support. Some barriers 
to HIV medication adherence are identified, including lack of knowledge and competence 
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regarding how to maintain good adherence [11, 23–26]; patient-provider relationship [8, 11, 
27, 28]; and psychosocial factors such as depression, anxiety, fatigue, and stress, as well as 
lack of social support and negative attitudes about the HIV disease [8, 11, 23–32].
The scientific literature focusing on developing and testing behavioral interventions to 
address identified barriers and help PLWH adhere to their medications continues to expand, 
particularly as PLWH are living longer and as medication regimens are evolving over time. 
Overall, the positive effects of these interventions on adherence behaviors and viral load has 
been highlighted through several quantitative and qualitative systematic reviews [25, 33–
38]. These reviews are useful for understanding the overall potential for interventions to 
improve medication adherence; however, they typically do not critically evaluate the study 
design, implementation, analysis, and strength of findings of individual interventions. Doing 
so may help identify model programs, with rigorous methods and strong findings, which 
could be used by prevention providers within their own clinics or communities. Therefore, 
there remains a need to supplement these reviews by identifying individual interventions 
with evidence of efficacy.
CDC’s HIV/AIDS Prevention Research Synthesis (PRS) Project
In order to identify evidence-based interventions (EBIs) for the HIV prevention field, the 
CDC established the HIV/AIDS PRS project in 1996 (http://www.cdc.gov/hiv/dhap/prb/prs/
index.html) [39]. The aim of the PRS project is to review and synthesize the cumulative 
body of evidence of HIV prevention interventions from the scientific research literature to 
help inform policy decisions and programmatic efforts within the U.S. and to guide future 
research. Since 1996, the PRS team has been conducting meta-analyses and systematic 
efficacy reviews focused on interventions to change sex and drug behaviors related to HIV 
acquisition and transmission. In late 2008, the PRS team expanded the scope to include 
medication adherence interventions and began a new systematic review to identify EBIs for 
improving HIV medication adherence among PLWH (referred to as “adherence EBIs”).
This article focuses on the findings from the PRS systematic efficacy review process for 
identifying adherence EBIs. First, we briefly describe methods for developing the efficacy 
criteria and the final criteria for evaluating adherence interventions. Second, we provide a 
summary of the adherence EBIs identified through our systematic review process and 
compare the EBIs to interventions that did not meet our efficacy review criteria. Finally, we 
provide recommendations for future programmatic and research activities.
Methods
PRS Efficacy Criteria for HIV Medication Adherence Interventions
Between 2008 and 2010, the PRS team conducted a series of activities to develop the 
efficacy criteria to evaluate the evidence from published HIV medication adherence 
intervention studies. These included repeated consultations with CDC scientists, key federal 
partners including the National Institute of Mental Health (NIMH), the National Institute of 
Drug Abuse (NIDA), and the Health Resources and Services Administration (HRSA), and 
non-federal researchers with substantial expertise in HIV medication adherence issues. The 
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existing PRS efficacy criteria for HIV-related sex and drug risk reduction interventions were 
used as the initial framework and were adapted to address issues relevant for adherence 
intervention studies.
To ensure a reasonable level of confidence that observed changes could be attributed to the 
intervention under evaluation, these criteria focus heavily on elements related to internal 
validity and assess risk of bias in individual studies (e.g., potential bias resulted from 
allocation method, reassignment, baseline group equivalence, attrition, measurement and 
confounding factors). The criteria assess factors across four domains: the quality of study 
design, quality of study implementation, quality of study analysis, and strength of evidence. 
Based on the overall set of criteria, adherence EBIs are classified as either good-evidence or 
best-evidence. Good-evidence interventions are considered to have been evaluated using 
scientifically sound methods and provide sufficient evidence of efficacy and must meet each 
element in the efficacy criteria (Table 1). Best-evidence interventions are considered to have 
been rigorously evaluated and provide the strongest evidence of efficacy and must meet 
additional elements within the efficacy criteria (Table 2). In Tables 1 and 2, we list the PRS 
efficacy criteria and indicate whether the criteria were supported by other systematic review 
or evidence-based groups, based on empirical evidence, or recommended by our consultants. 
Appendix A in supplementary material provides more detailed explanation on the complex 
elements of our efficacy criteria.
Systematic Search Strategy
Two librarians with expertise in systematic searches developed and conducted a 
comprehensive and systematic search strategy, including both annual automated and 
quarterly manual searches, to identify all relevant HIV medication adherence intervention 
reports for the PRS cumulative database. The annual automated search component focused 
on literature published between 1996 and 2011 using the following electronic databases and 
platforms: CINAHL (EBSCOhost platform), EMBASE (OVID), MEDLINE (OVID), and 
PsycINFO (OVID). We selected 1996 as the start date for our search to be consistent with 
the year that HAART was made more available to HIV positive persons in the U.S. The 
automated search component used indexing and keyword terms, cross-referenced using 
Boolean logic, in four areas: (a) HIV/AIDS; (b) intervention and prevention evaluation; (c) 
HAART, anti-retroviral therapy or treatment; and (d) adherence. Indexing terms for the 
electronic searches were varied according to each database, but keywords remained constant 
across all databases and searches. The search was not restricted by country or language. The 
last automated search for this efficacy review was conducted in March 2012. As required by 
the PRISMA checklist, the full search strategy of the MEDLINE database is provided in 
Appendix B in supplementary material. The searches of the other databases are available 
from the corresponding author.
The quarterly manual search component involved reviewing all articles published in the 
previous 3 months of 20 journals to identify potentially relevant articles not yet indexed in 
electronic databases (see Appendix C in supplementary material). The last quarterly manual 
search for this review was conducted in January 2012. To supplement our routine automated 
and manual searches, PRS also examined the reference lists of relevant published articles, 
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HIV/AIDS Internet listserves (e.g., www.RobertMalow. org), various research databases 
(i.e., ISI Web of Knowledge, RePORTER, Cochrane), and unpublished manuscripts 
submitted by study authors. Further details of the supplemental searches can be obtained 
from the corresponding author.
Study Selection
We searched the CDC’s PRS database for eligible studies. Studies were included for the 
efficacy review if they (1) were conducted in the U.S. or a U.S. territory; (2) were published 
or accepted for publication between 1996 and 2011; (3) reported on an intervention that 
focused on improving HIV medication adherence among PLWH by including either an 
educational or behavioral component (i.e., excluding studies exclusively comparing drug 
regimens), treatment delivery method (e.g., directly administered antiretroviral therapy 
[DAART]), or monitoring device to facilitate adherence (e.g., pager); (4) compared an 
intervention group to a comparison group; and (5) reported data on at least one behavioral 
adherence outcome (i.e., as measured by medication event monitoring system [MEMS caps], 
electronic data monitoring [EDM], pill count, self-report, or pharmacy refill) or laboratory-
based HIV viral load outcome (i.e., not self-report). Our review allowed for behavioral 
interventions delivered to individuals, small groups or communities, but excluded 
interventions that were exclusively changes in policy or structure. Linked citations, defined 
as publications providing additional information on the same study, were included in this 
efficacy review if they provided relevant intervention evaluation information.
Qualitative Data Coding
Pairs of trained coders independently evaluated each eligible intervention against the newly 
established efficacy criteria on study design, implementation, analysis, and strength of 
findings. The reliability between coders on the efficacy coding was not calculated. All the 
coders go through standardized and stringent coding training and, on average, the overall 
percentage agreement among the trained coders is 96 % with a kappa rate of 80 % on our 
regular citation-level coding, indicating a high inter-rater reliability. All discrepancies were 
reconciled between paired coders. The first author of individual studies was contacted to 
provide missing data or clarification as needed. Of the 15 authors (out of 57 studies) we 
contacted for additional information, the response rate was 87 %. Final efficacy 
determination for each study was reached by PRS group consensus.
Results
PRS evaluated 65 interventions from the 57 unique studies eligible for this efficacy review 
(Fig. 1). Of these, we identified 10 interventions from 9 unique studies that met the good-
evidence efficacy criteria and are considered evidence-based [40–48]. Fifteen percent of 
eligible medication adherence interventions (i.e., 10/65) met the PRS efficacy criteria. 
Below, we describe the characteristics of the 10 EBIs.
Population Characteristics of EBIs
All of the EBIs targeted adults. As shown in Table 3, eight interventions targeted clinic 
patients [40–43, 45, 47, 48] and two targeted drug users [40, 44]. None of the EBIs 
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specifically targeted men who have sex with men (MSM), although one targeting discordant 
couples included gay male couples [46] and one included a majority of MSM participants 
[45]. One intervention targeted treatment-naïve individuals initiating therapy [43], four 
targeted treatment-experienced individuals [41, 45, 46, 48], and five included both 
treatment-experienced and -naïve individuals [40, 42, 44, 47].
All 10 EBIs had greater than 50 % minority participants (range 53–94 %), six of which 
included a majority of African Americans [40–44, 46]. In addition, all 10 interventions had 
greater than 50 % male participants (range 52–88 %), and participants ranged in age from 19 
to 67 years.
Intervention Characteristics of EBIs
Overall, there were three discrete interventions, defined as those in which participants had to 
receive all intervention sessions [41, 42, 46], two repetitive dosing interventions, defined as 
those in which sessions were implemented repeatedly without an explicit end point (both 
DAART; [40, 44]), and 5 EBIs with both discrete and repetitive dosing components [43, 45, 
47, 48] (see Appendix A in supplementary material for detailed description of length of 
follow-up criteria). All EBIs, except for the two delivering DAART, relied on at least 1 
behavioral change theory or model such as Social Cognitive Theory [49], Social Support 
Theory [50], Self-determination Theory [51], the Social Problem Solving Model [52], Paolo 
Freire’s Educational Model [53], and Social Action Theory [54].
As shown in Table 4, six EBIs were delivered in public or private outpatient clinics (one of 
which was also implemented in community-based organizations [41, 42]). Additional 
intervention settings included a mobile community health care van [40], anywhere the 
patient had access to a pager [47], and residential and community settings [48]. The 
interventions were delivered by a health care provider such as a nurse (n = 5), peer (n = 3), 
community/outreach worker (n = 2), or facilitator (n = 3). All EBIs included components 
delivered to individuals, except SMART Couples [46] which was group-based. Three 
interventions included both individual and group components: Project HEART [43], the 
Integrated HIV Risk Reduction and Adherence Intervention [42], and Peer Support [47].
Although the content of the EBIs differed substantially, the majority of the interventions 
included a cognitive-behavioral component (e.g., addressing barriers to adherence and 
problem-solving). Three interventions focused on skill-building: technical (e.g., practice 
medication adherence with candies), personal (e.g., practice ways to overcome barriers), and 
interpersonal (e.g., couple communication exercises). In addition to medication adherence, 
one EBI focused on patient-provider relationships in clinic settings [45], and three focused 
on both medication adherence and safer sex [41, 42, 46]. Social support was also 
incorporated as an important component in three EBIs [43, 46, 47].
Outcomes Measures of EBIs
Among the ten EBIs, one measured viral load only [44], two measured adherence behavior 
only [41, 42], and the remaining seven measured both viral load and adherence behavior. 
Among the nine interventions that measured adherence behavior, three relied on MEMS 
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caps only [43, 46, 48], two relied on EDM data and self-report ([47] Peer Support and Pager 
Messaging), one relied on unannounced pill counts and pharmacy prescription records [42] 
and three relied on self-report only [40, 41, 45].
Among the seven EBIs that assessed viral load and adherence behavior, three observed a 
significant intervention effect on viral load only and three on adherence behavior only. Only 
one found a significant intervention effect on both outcomes [45]. Significant intervention 
effects were observed over a range of follow-up times, from 3 to 18 months post-initiation 
of the seven interventions with repetitive-dosing components and 1–13 months post-
completion of the three discrete interventions [41, 42, 46].
Reasons for Not Meeting Best-Evidence Criteria
The ten good-evidence interventions did not meet the best-evidence efficacy criteria for the 
following reasons (not mutually exclusive): did not find a significant positive intervention 
effect on both behavioral and biologic measures of adherence (n = 9; three of these did not 
measure both outcomes); did not meet the requirement for retention (n = 2) or follow-up 
time point (n = 3), did not impute missing data (n = 4) or adjust for clusters (n = 2). One 
additional study was identified as a non-RCT with moderate allocation bias. Most of these 
limitations are a result of the design of the study and/or analysis of data.
Comparison Between EBIs and Non-EBIs
Although 10 interventions were identified as EBIs, 55 interventions from 48 unique studies 
[55–102] did not meet the minimal criteria for good-evidence. The most common reasons 
(not mutually exclusive) were: small sample size (n = 31; 56 %), null/non-significant 
findings (n = 18; 33 %), no appropriate follow-up (n = 12; 22 %), poor retention (n = 7; 13 
%). Several studies had other design or analytic issues that did not meet criteria (n = 9; 22 
%; e.g., biased allocation to study arms, harmful negative effects, substantial missing data). 
The comparisons between the 10 EBIs and the 55 non-EBIs on key population and 
intervention characteristics are shown in Table 5. Both groups are similar on several 
population and intervention characteristics; however, there are a couple notable differences. 
All of the EBIs had at least one positive significant outcome (100 %) whereas only two-third 
(64 %) of the non-EBIs did. More EBIs than non-EBIs targeted both treatment-experienced 
and -naïve patients combined (50 vs. 7 %). Additionally, more non-EBIs than EBIs focused 
on specific populations (e.g., women only, men only, high risk youth only); whereas, more 
EBIs include a majority of African American participants than non-EBIs (60 vs. 49 %).
Discussion
Given the importance of adherence for both prevention and treatment efficacy, it is very 
encouraging to have identified 10 EBIs for promoting adherence among PLWH. These 
interventions can serve as model programs for providers and other prevention planners 
looking to implement EBIs best suited for their community’s needs.
The 10 EBIs represent 15 % of eligible interventions (i.e., 10/65) for this first efficacy 
review of HIV medication adherence interventions. In comparison, the first published PRS 
sex and drug risk reduction efficacy review, which included a review of the scientific 
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literature, published from 2000 to 2004, identified 18 % of eligible interventions as meeting 
the original PRS efficacy criteria [103]. Over the years, the scientific field has evolved, with 
advancements in research and improvements in study quality. Cumulatively, through 2011, 
roughly 20–22 % of the eligible risk reduction behavioral interventions have met the risk 
reduction efficacy criteria (personal correspondence with PRS team, 2011). The results of 
this medication adherence efficacy review are comparable to those initial findings for risk 
reduction interventions. Similarly, we anticipate an increase in medication adherence EBIs 
over time as the field matures. To remain a valuable source to HIV-care and prevention 
providers, the PRS team plans to continually update this review and post new adherence 
EBIs on the PRS website (http://www.cdc.gov/hiv/prevention/research/compendium/ma/
index.html) as they are identified.
The 55 interventions that did not meet the efficacy criteria reported similar population and 
intervention characteristics but failed to meet evidence-based criteria, primarily due to small 
sample sizes, null findings or low retention rates. Among these 55 interventions, 35 (64 %) 
found at least 1 significant positive intervention effect. These interventions could be 
considered for re-testing, in particular with more rigorous evaluation methods.
Although the study samples across the 10 EBIs consist of greater than 50 % minority 
participants, we do not know specifically the percentage of MSM of color or minority 
women across these studies. Non-EBIs more often targeted specific populations (e.g., 
women, high-risk youth, MSM, men) whereas the EBIs more often targeted general clinic 
populations. Given that the EBIs tended to target the general HIV clinic population, this 
suggests that these effects may be robust and can be generalized to a wide variety of HIV 
care clinics. One exception may be HIV-positive injection drug users (IDUs) since their 
lifestyle and active substance use may create a barrier to adherence that others may not 
experience. The two EBIs targeting drug users were DAART interventions, which may not 
be easily implementable or sustainable in typical HIV clinics. Systematic reviews of 
DAART interventions have shown them to be efficacious during implementation but not so 
after DAART services end. Future research should evaluate the extent to which current and 
newly developed interventions are effective for IDUs, drug users, and other groups with 
unique structural barriers (such as homeless persons) to adherence.
Those involved in developing and implementing HIV medication adherence interventions 
also have the opportunity to engage PLWH at the onset of treatment and to help them 
establish a high level of adherence from the beginning. Of the ten EBIs, only one focuses 
exclusively on treatment-naïve participants [43]. There is opportunity here for providers to 
identify participants as soon as they are linked to care and assist them in developing and 
maintaining good adherence behaviors.
A few limitations of this review and the literature warrant comment. First, our criteria 
primarily focused on internal validity and did not focus on evidence from replication studies, 
external validity, scalability, cost and population-level impact which should be incorporated 
in the criteria as the medication adherence field advances. Second, our criteria are designed 
to evaluate risk of bias in individual studies; however, there is a potential risk of bias across 
studies in our review as we only evaluated published reports. Third, there remains 
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considerable variability regarding a “gold standard” for adherence measurement in research 
and practice. As recently recommended by Williams and her colleagues, the prevention field 
is encouraged to adopt quality standards for measuring and reporting on adherence measures 
so that adherence behaviors are reported consistently and reliably [104].
Despite these limitations, there are a few implications from our review findings for further 
research. For improving the quality of study design, implementation, and analyses, 
researchers should aim to assess both behavioral and biologic measures of adherence, 
develop strategies to retain participants over longer periods of time (particularly among 
prioritized populations and those known to have poor retention in care), and use robust 
analytic methods for dealing with complex data that result from missing data and design 
elements (e.g., allocating clusters of individuals). We also encourage researchers to use the 
PRS efficacy criteria to evaluate their own interventions as they are being developed. The 
current fiscal environment requires a deliberate effort to identify and support the 
interventions most likely to have a large impact on the HIV epidemic. It is imperative that 
EBIs are also evaluated to determine which ones are most easily scalable and cost-effective. 
Researchers, therefore, are further encouraged to report cost data related to intervention 
implementation.
Translating EBIs into Practice
Similar to recommendations in other public health sectors, [105, 106] the National HIV/
AIDS Strategy [1] calls for greater focus on evidence-based HIV prevention by drawing 
upon interventions and strategies with proven efficacy. Thus, once EBIs are identified, they 
need to be made available and accessible for wide-scale use in practice to achieve a larger 
public health impact. Many of the HIV risk reduction interventions previously identified by 
PRS as EBIs (http://www.cdc.gov/hiv/prevention/research/compendium/index.html) have 
been translated into easy-to-use intervention materials and are being disseminated to 
prevention providers across the nation (https://www.effectiveinterventions.org) [107]. 
Recently, CDC has developed web-based and e-learning training and implementation 
materials for five of these medication adherence EBIs for national dissemination and wide-
spread practice (https://www.effectiveinterventions.org) [107]. These interventions were 
designed for healthcare and/or non-healthcare providers. For clinic settings, there is a need 
for brief intervention tools that are feasible to be implemented within the short period of 
time that providers have with their patients during routine HIV care. The more intensive 
EBIs can be more realistically implemented in non-healthcare settings to provide additional 
support to improve PLWH’s ART adherence behavior. Efforts in both healthcare and non-
healthcare settings are important to fully support PLWH in achieving optimal adherence to 
ART and viral load suppression.
Conclusions
This efficacy review contributes to the research translation of HIV medication adherence 
interventions; that is, translating proven scientific research into routine practice. Our 
systematic review identified several EBIs that can serve as model programs for providers 
and other prevention planners who are looking to implement evidence-based HIV 
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medication adherence interventions best suited for their community’s needs. The medication 
adherence field can be further improved if identified research opportunities are explored. 
Scalable, cost-effective, evidence-based adherence interventions are imperative for 
improving the health outcomes and reducing HIV transmission risk among PLWH.
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Table 1
PRS criteria for good-evidence medication adherence behavioral interventions
Intervention description
Clear description of key aspects of the interventiona
Quality of study design
At least a quasi-prospective study designa
Appropriate comparison arma
At least a non-concurrent comparison arm that was implemented within 12 months of the start of the intervention and was similar with respect 
to population characteristics and settingc
At least non-random allocation with minimal or moderate selection bias unrelated to the intervention or adherence behaviora
Quality of study implementation
At least a 1-month post-intervention follow-up assessment for each study arm (with recall not referring to pre-intervention period) for 
interventions that are clearly discrete or at least a 3-months post-initiation follow-up assessment for each study arm for all other types of 
interventionsc
At least a 60 % retention rate (or medical chart recovery) at a single required assessment time point for each study armb
Quality of study analysis
Analysis contrasting intervention arm and an appropriate comparison arma
Intent-to-treat analysis
 Analysis of participants in study arms as originally allocateda
 Analysis of participants regardless of the level of intervention exposurea
Comparability of measures
 Measures must be identical, including recall, for any repeated measures or change score analysesa
 Baseline measures do not have to be identical, but must be of the same construct as outcome measures, if used as a covariate in analyses (i.e., 
adjusted for BL)a
Analysis based on a 2-sided test and an α = .05 (or more stringent)a
Analytic sample of at least 40 participants in each study arma
Non-randomized controlled trials (non-RCTs) must either demonstrate baseline equivalence or control for baseline differences in outcome 
variables. Non-RCTs with moderate bias or non-concurrent comparison must also demonstrate baseline equivalence or control for baseline 
differences in demographics and other critical variablesa
Strength of evidence—significant positive intervention effects
Positive and statistically significant (p ≤ .05) intervention effect for at least 1 relevant behavioral outcome measure or 1 relevant biologic 
outcome measure(defined as greater improvement in, or better level of, medication adherence behavioral or biologic outcome in the intervention 
arm relative to the comparison arm)a
 A relevant behavioral outcome measure may include electronic data monitoring (e.g., MEMs caps), pill count, pharmacy refill, or self-
reported adherence.
  A relevant biologic outcome measure may include a lab test or medical chart recovery of HIV viral load levelsc
Effect at the follow-up and based on the analyses that meet study design, implementation and analysis criteriac
Strength of evidence—significant negative intervention effects
No negative and statistically significant (p ≤ .05) intervention effect for any relevant outcomea
 A negative intervention effect is defined as a statistically significant greater improvement in, or better level of, HIV-related behavioral or 
biologic outcomes in the comparison arm relative to the intervention arm.
No other statistically significant harmful intervention effect on other outcomesa
For intervention with a replication evaluation, no significant negative intervention effectsa
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Additional limitations to evaluate
The totality of the limitations (as described below) cannot introduce considerable bias that substantially reduces the confidence placed on the 
findings
Examples of limitations to check
 Intervention and comparison arms did not receive similar medication regimensc
 Findings based on too many post hoc analysesa
 Inconsistent evidence between effectsa
 Inconsistent evidence across intervention comparisons within the studya
 Effects only found within a potentially biased subgroup analysisa
 Substantial (>40 %) overall missing data (due to attrition and non-attrition such as missing responses)c
 Substantial differential attrition in rates (>10 %) or participant characteristics across study armsa
 Differences in characteristics between those lost-to-follow up and those retained in the studya
 Any other notable bias threatening internal or external validitya
a
Supported by other systematic review or evidence-based groups such as HHS-Office of the Assistant Secretary for Health (http://
www.hhs.gov/ash/oah), Community Guide (http://www.thecommunityguide.org/index.html), Department of Education—Institute of Education 
Science (http://ies.ed.gov/ncee/wwc/), HHS—Administration for Children and Family (http://homvee.acf.hhs.gov/Default.aspx), Office of Justice 
Programs (http://www.crimesolutions.gov/), Promising Practices Network (http://www.promisingpractices.net/), or Coalition for Evidence-Based 
Policy (http://toptierevidence.org/; http://evidencebasedprograms.org/)
b
Based on empirical evidence
c
Recommended by consultants only
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Table 2
Additional elements for PRS best-evidence medication adherence behavioral interventions
Intervention description
(No additional elements for best-evidence)
Quality of study design
Prospective study designa
Concurrent comparison arma
Random allocation of participants to study armsa
Quality of study implementation
At least a 3-month post-intervention follow-up assessment for each study arm (with recall referring to post-intervention period only) for 
interventions that are clearly discrete or at least a 6-months post-initiation follow-up assessment for each study arm for all other types of 
interventionsc
At least a 70 % retention rate (or medical chart recovery) at a single required assessment time point for each study armb
Quality of study analysis
Intent-to-treat analysis
 Analysis using appropriate imputations to account for missing data due to attrition or other reasonsc
Use of appropriate cluster-level analyses if allocated to study arms by clustera
Analytic sample of at least 50 participants in each study arma
Strength of evidence—significant positive intervention effects
Positive and statistically significant (p ≤ .05) intervention effect for at least 1 relevant behavioral outcome measure and 1 relevant biologic 
outcome measure
a
Supported by other systematic review or evidence-based groups such as HHS-Office of the Assistant Secretary for Health (http://
www.hhs.gov/ash/oah), Community Guide (http://www.thecommunityguide.org/index.html), Department of Education—Institute of Education 
Science (http://ies.ed.gov/ncee/wwc/), HHS—Administration for Children and Family (http://homvee.acf.hhs.gov/Default.aspx), Office of Justice 
Programs (http://www.crimesolutions.gov/), Promising Practices Network (http://www.promisingpractices.net/), or Coalition for Evidence-Based 
Policy (http://toptierevidence.org/; http://evidencebasedprograms.org/)
b
Based on empirical evidence
c
Recommended by consultants only
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Table 5
Comparison of characteristics of EBIs and non-EBIs included in the PRS efficacy review (N = 65)
Characteristic 10 EBIs n (%) 55 non-EBIs n (%)
Target population
 MSM 0 (0) 1 (2)
 Drug users/IDU only 2 (20) 9 (16)
 High risk youth only 0 (0) 3 (5)
 Women only 0 (0) 9 (16)
 Men only 0 (0) 2 (4)
Race/ethnicity (not mutually exclusive)
 Majority AA 6 (60) 27 (49)
 Majority people of color (including AA, Hispanic, API, other) 5 (50) 26 (47)
 Majority white 0 (0) 5 (9)
Target groupa
 Treatment-experienced 4 (40) 27 (49)
 Treatment-naïve 1 (10) 18 (33)
 Both 5 (50) 4 (7)
Type of setting (not mutually exclusive)
 Clinic 6 (60) 34 (62)
 Community 4 (40) 1 (2)
 Other 2 (20) 34 (62)
Unit of delivery
 Individual only 6 (60) 41 (75)
 Group only 1 (10) 6 (11)
 Individual and group 3 (30) 8 (15)
 Community 0 (0) 0 (0)
Deliverer (not mutually exclusive)
 Clinic staff 6 (60) 24 (44)
 Facilitator/other 7 (70) 41 (75)
Intervention sessions
 Single-session discrete 0 (0) 2 (4)
 Multi-session discrete 3 (30) 25 (45)
 Repetitive dosing or combinationb 7 (70) 28 (51)
Outcomes measured
 Adherence only 2 (20) 19 (35)
 Viral load only 1 (10) 5 (9)
 Both 7 (70) 31 (56)
At least one statistically significant positive intervention effectc
 Yes 10 (100) 35 (64)
 No 0 (0) 20 (36)
Sample size at baseline
 Median 226 77
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Characteristic 10 EBIs n (%) 55 non-EBIs n (%)
Follow-up time
 Median time for first follow-up (in month) 3 2
 Median time for last follow-up (in month) 9 6
Median retention
 At first “good-evidence” follow-upd 85 % 81 %
a
n = 6 non-EBIs did not target treatment naïve or experienced
b
Repetitive dosing or combination = includes interventions that had repetitive dosing and one or more discrete sessions
c
At least one statistically significant positive intervention effect on viral load or medication adherence outcomes
d
1-month post completion of intervention or 3-month post implementation of intervention
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